<article xmlns="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle http://dtd.nlm.nih.gov/2.0/xsd/archivearticle.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Chem Biol</journal-id>
      <journal-title-group>
        <journal-title>Chemistry &amp; Biology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1074-5521</issn>
      <issn pub-type="epub">1879-1301</issn>
      <publisher>
        <publisher-name>Elsevier</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3032886</article-id>
      <article-id pub-id-type="pmid">21095575</article-id>
      <article-id pub-id-type="publisher-id">CHBIOL1789</article-id>
      <article-id pub-id-type="doi">10.1016/j.chembiol.2010.09.014</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Cell-Penetrant, Nanomolar <italic>O</italic>-GlcNAcase Inhibitors Selective against Lysosomal Hexosaminidases</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Dorfmueller</surname>
            <given-names>Helge C.</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Borodkin</surname>
            <given-names>Vladimir S.</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Schimpl</surname>
            <given-names>Marianne</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zheng</surname>
            <given-names>Xiaowei</given-names>
          </name>
          <xref rid="aff1" ref-type="aff">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kime</surname>
            <given-names>Robert</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Read</surname>
            <given-names>Kevin D.</given-names>
          </name>
          <xref rid="aff2" ref-type="aff">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>van Aalten</surname>
            <given-names>Daan M.F.</given-names>
          </name>
          <email>dmfvanaalten@dundee.ac.uk</email>
          <xref rid="aff1" ref-type="aff">1</xref>
          <xref rid="cor1" ref-type="corresp">∗</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Division of Molecular Microbiology, College of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland</aff>
      <aff id="aff2"><label>2</label>Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland</aff>
      <author-notes>
        <corresp id="cor1"><label>∗</label>Corresponding author <email>dmfvanaalten@dundee.ac.uk</email></corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <day>24</day>
        <month>11</month>
        <year>2010</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. -->
      <pub-date pub-type="ppub">
        <day>24</day>
        <month>11</month>
        <year>2010</year>
      </pub-date>
      <volume>17</volume>
      <issue>11</issue>
      <fpage>1250</fpage>
      <lpage>1255</lpage>
      <history>
        <date date-type="received">
          <day>21</day>
          <month>6</month>
          <year>2010</year>
        </date>
        <date date-type="rev-recd">
          <day>24</day>
          <month>8</month>
          <year>2010</year>
        </date>
        <date date-type="accepted">
          <day>1</day>
          <month>9</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2010 Elsevier Ltd.</copyright-statement>
        <copyright-year>2010</copyright-year>
        <copyright-holder>Elsevier Ltd</copyright-holder>
        <license>
          <license-p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract>
        <title>Summary</title>
        <p>Posttranslational modification of metazoan nucleocytoplasmic proteins with N-acetylglucosamine (<italic>O</italic>-GlcNAc) is essential, dynamic, and inducible and can compete with protein phosphorylation in signal transduction. Inhibitors of <italic>O</italic>-GlcNAcase, the enzyme removing <italic>O</italic>-GlcNAc, are useful tools for studying the role of <italic>O</italic>-GlcNAc in a range of cellular processes. We report the discovery of nanomolar OGA inhibitors that are up to 900,000-fold selective over the related lysosomal hexosaminidases. When applied at nanomolar concentrations on live cells, these cell-penetrant molecules shift the <italic>O</italic>-GlcNAc equilibrium toward hyper-<italic>O</italic>-GlcNAcylation with EC<sub>50</sub> values down to 3 nM and are thus invaluable tools for the study of <italic>O</italic>-GlcNAc cell biology.</p>
      </abstract>
      <abstract abstract-type="graphical">
        <title>Highlights</title>
        <p>► Structure-guided design of human <italic>O</italic>-GlcNAcase inhibitors, GlcNAcstatins ► The GlcNAcstatins are competitive, nanomolar inhibitors ► The molecular basis of the exquisite selectivity revealed by crystallography ► First direct evidence of <italic>O</italic>-GlcNAcase inhibitors penetrating cells</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <sec id="sec1">
      <title>Introduction</title>
      <p>The <italic>O</italic>-GlcNAc modification was discovered more than two decades ago by <xref rid="bib23" ref-type="bibr">Torres and Hart (1984)</xref>. This modification consists of a single GlcNAc sugar that is dynamically and reversibly transferred onto/hydrolyzed from serine/threonine residues on proteins in the nucleocytoplasm (<xref rid="bib10 bib9" ref-type="bibr">Hart et al., 2007; Hanover et al., 2010</xref>). Similar to protein phosphorylation, the <italic>O</italic>-GlcNAc modification has been shown to be involved in signaling processes and to occupy serine/threonine residues identical, or adjacent, to known protein phosphorylation sites (<xref rid="bib21 bib3 bib26 bib10" ref-type="bibr">Roquemore et al., 1996; Chou et al., 1992; Zachara and Hart, 2006; Hart et al., 2007</xref>). <italic>O</italic>-GlcNAc transfer is performed by a single enzyme, the <italic>O</italic>-GlcNAc transferase (OGT) (<xref rid="bib11 bib14" ref-type="bibr">Kreppel et al., 1997; Lubas et al., 1997</xref>). The <italic>O</italic>-GlcNAc modification is removed by a single enzyme termed <italic>O</italic>-GlcNAcase (OGA) (<xref rid="bib8" ref-type="bibr">Gao et al., 2001</xref>).</p>
      <p>A range of approaches has been used to gain insight into the function of <italic>O</italic>-GlcNAc and its possible regulation of signaling pathways, including genetic manipulation (<xref rid="bib2 bib20" ref-type="bibr">Bowe et al., 2006; Ngoh et al., 2009</xref>) and blocking <italic>O</italic>-GlcNAc hydrolysis with small molecules that inhibit hOGA. A number of hOGA inhibitors have been described and used to demonstrate the involvement of <italic>O</italic>-GlcNAc in the insulin response (<xref rid="bib1" ref-type="bibr">Akimoto et al., 2007</xref>), regulation of Tau phosphorylation (<xref rid="bib25" ref-type="bibr">Yuzwa et al., 2008</xref>), Akt activation (<xref rid="bib24" ref-type="bibr">Vosseller et al., 2002</xref>), and, recently, in regulation of cellular volume (<xref rid="bib19" ref-type="bibr">Nagy et al., 2009</xref>). However, many of these inhibitors possess limited selectivity over the structurally related lysosomal hexosaminidases A/B (HexA/B) and/or are only active on cells in the high micromolar range, increasing the risk of off-target effects, as suggested recently by <xref rid="bib16 bib25" ref-type="bibr">Macauley et al. (2008), Yuzwa et al. (2008)</xref>, and <xref rid="bib5 bib6" ref-type="bibr">Dorfmueller et al. (2006, 2009)</xref>.</p>
      <p>Here we have attempted to target a conserved hOGA active site cysteine with suicide inhibitors, based on the GlcNAcstatin scaffold. These novel compounds are up to 900000-fold selective over HexA/B, penetrating the OGA active site as revealed by X-ray crystallography. The compounds penetrate live cells, inducing hyper-<italic>O</italic>-GlcNAcylation when used at low nanomolar concentrations. The new GlcNAcstatins will be useful tools for studying the role of <italic>O</italic>-GlcNAc in cellular signaling pathways.</p>
    </sec>
    <sec id="sec2">
      <title>Results and Discussion</title>
      <sec id="sec2.1">
        <title>Design of Novel GlcNAcstatin-Based Suicide OGA Inhibitors</title>
        <p>GlcNAcstatins (<xref rid="fig1" ref-type="fig">Figure 1</xref>A), a novel family of potent human OGA inhibitors, have recently been reported to possess 150-fold selectivity over hHexA/B (<xref rid="bib5 bib6" ref-type="bibr">Dorfmueller et al., 2006, 2009</xref>). Based on the structural data of GlcNAcstatins in complex with a bacterial OGA from <italic>C</italic>. <italic>perfringens</italic> (<italic>Cp</italic>OGA) (<xref rid="fig2" ref-type="fig">Figure 2</xref>A), we assumed that increased selectivity for hOGA over the HexA/B could be achieved by extending the size of the <italic>N</italic>-acyl derivative. However, similar elaboration of the NAG-thiazoline/PUGNAc scaffolds reduced inhibition from nanomolar to micromolar range (<xref rid="bib15 bib22" ref-type="bibr">Macauley et al., 2005; Stubbs et al., 2006</xref>). A structural comparison of the active site pockets from <italic>Cp</italic>OGA (<xref rid="bib6" ref-type="bibr">Dorfmueller et al., 2009</xref>) and hHexA (<xref rid="bib13" ref-type="bibr">Lemieux et al., 2006</xref>) and hHexB (<xref rid="bib17" ref-type="bibr">Mark et al., 2003</xref>) reveals obvious differences in the <italic>N</italic>-acetyl binding pocket (<xref rid="fig2" ref-type="fig">Figure 2</xref>A). The β-hexosaminidases have a narrower (difference of approximately 1.4 Å) and shallower (difference of approximately 5.0 Å) pocket than the OGA enzymes (<xref rid="fig2" ref-type="fig">Figure 2</xref>A). Interestingly, a cysteine residue is located at the bottom of the hOGA active site (Cys215) (<xref rid="fig2" ref-type="fig">Figure 2</xref>B). This cysteine is conserved in metazoan OGAs, and hOGA is potently inhibited by a thiol-reactive compound (<xref rid="bib4" ref-type="bibr">Dong and Hart, 1994</xref>).</p>
        <p>In an attempt to generate a potent, selective hOGA “suicide” inhibitor, the <italic>N</italic>-acyl group of GlcNAcstatin D was extended and modified to contain thiol-reactive groups that could irreversibly react with the cysteine located in a pocket at the bottom of the active site. GlcNAcstatin F carries a 3-mercaptopropanamide side chain (<xref rid="fig1" ref-type="fig">Figure 1</xref>A) and GlcNAcstatin G a penta-2,4-dienamide derivative, both potentially able to react with the hOGA Cys215. GlcNAcstatin H, a saturated derivative of GlcNAcstatin G, was synthesized as a control (<xref rid="fig1" ref-type="fig">Figure 1</xref>A). The synthesis will be reported elsewhere.</p>
      </sec>
      <sec id="sec2.2">
        <title>GlcNAcstatins F–H Show Increased hOGA Selectivity while Retaining Potency</title>
        <p>The new GlcNAcstatin derivatives were evaluated in kinetic studies for their ability to inhibit recombinant hOGA. The pH optimum of hOGA is 7.3 (<xref rid="fig1" ref-type="fig">Figure 1</xref>D), whereas the first GlcNAcstatin inhibitor reported (GlcNAcstatin C) inhibits with maximum potency at pH 6.6 (K<sub>i</sub> = 2.9 nM) (<xref rid="fig1" ref-type="fig">Figure 1</xref>D). At pH 7.3, GlcNAcstatins F–H show time-independent inhibition in the 2.6–11.2 nM range (<xref rid="tbl1" ref-type="table">Table 1</xref> and <xref rid="fig1" ref-type="fig">Figures 1</xref>A and 1B). To assess selectivity, inhibition of hHexA/B was also investigated (<xref rid="fig1" ref-type="fig">Figure 1</xref>C). The extension of the <italic>N</italic>-propionyl side chain of GlcNAcstatin D with an additional thiol group (GlcNAcstatin F) increases selectivity for hOGA to 1000-fold (<xref rid="fig1" ref-type="fig">Figure 1</xref>C and <xref rid="tbl1" ref-type="table">Table 1</xref>), showing that the elongated <italic>N</italic>-acyl substitution abolishes the binding of the compound to hHexA/B (<xref rid="tbl1" ref-type="table">Table 1</xref>). Strikingly, the more extended GlcNAcstatin G inhibits hHexA/B with an approximate IC<sub>50</sub> of only 7 mM (<xref rid="fig1" ref-type="fig">Figure 1</xref>C and <xref rid="tbl1" ref-type="table">Table 1</xref>), thus resulting in a &gt;900,000-fold selectivity for GlcNAcstatin G toward hOGA, representing the most selective hOGA inhibitor reported to date.</p>
      </sec>
      <sec id="sec2.3">
        <title>The 3-Mercaptopropanamide Side Chain of GlcNAcstatin F Efficiently Occupies the Selectivity Pocket</title>
        <p>The molecular basis of the increased selectivity of the new GlcNAcstatin derivatives was investigated by X-ray crystallography using the <italic>Cp</italic>OGA V331C mutant that perfectly mimics the hOGA active site (<xref rid="bib6" ref-type="bibr">Dorfmueller et al., 2009</xref>) (<xref rid="fig2" ref-type="fig">Figure 2</xref>B). The <italic>Cp</italic>OGA-V331C GlcNAcstatin F complex (2.5 Å resolution) reveals that the inhibitor-binding mode is similar to the previously reported GlcNAcstatin C/D complexes (<xref rid="bib5 bib6" ref-type="bibr">Dorfmueller et al., 2006, 2009</xref>) (<xref rid="fig2" ref-type="fig">Figure 2</xref>B). The 3-mercaptopropanamide moiety points straight into the pocket of the active site, whereas all hydrogen bonds seen in the GlcNAcstatin C/D complexes are conserved. Interestingly, the sulfhydryl group of GlcNAcstatin F approaches the active site cysteine (Cys215 in hOGA, equivalent to Cys331 in the V331C-<italic>Cp</italic>OGA mutant) to within 3.5 Å (<xref rid="fig2" ref-type="fig">Figure 2</xref>B), although the side chain thiol points away from the inhibitor, and no disulfide bond is formed, in agreement with the absence of time-dependent inhibition. A structural superposition of the GlcNAcstatin F-V331C-<italic>Cp</italic>OGA complex onto the structure of hHexA (<xref rid="fig2" ref-type="fig">Figure 2</xref>C) reveals that the shallower <italic>N</italic>-acetyl binding pocket in the HexA structure would produce steric clashes with the 3-mercaptopropanamide moiety, also explaining the increased selectivity for hOGA of &gt;900,000-fold for the further elongated penta-2,4-dienamide substituent (GlcNAcstatin G).</p>
      </sec>
      <sec id="sec2.4">
        <title>GlcNAcstatin G Penetrates HEK293 Cells</title>
        <p>No direct evidence has so far been provided for any known hOGA inhibitor penetrating the cell and inducing cellular hyper-<italic>O</italic>-GlcNAcylation by direct inhibition of intracellular hOGA. We have used a mass-spectrometric approach to measure intracellular GlcNAcstatin G concentrations in HEK293 cells. HEK293 cells were treated in triplicate with two inhibitor concentrations (1 and 10 μM) for 1.5 and 6 hr. An equal number of cultured cells were lysed, and the intracellular volume was investigated by UPLC-MS/MS. On the basis of the average cell size (13.1–15.7 μm) and the number of cultured cells (1.4 × 10<sup>6</sup> to 2.2 × 10<sup>6</sup>), the maximal cellular volume and, thus, the minimal dilution factor of the intracellular volume upon the addition of lysis buffer were calculated (280-fold). Treatment of HEK293 cells with 10 μM GlcNAcstatin G resulted in a minimal inhibitor concentration of 270 nM after 1.5 hr and 380 nM after 6 hr. Application of a 1 μM extracellular concentration resulted in a 10-fold lower intracellular concentration of at least 30 and 40 nM, after 1.5 and 6 hr treatment, respectively. To our knowledge, these data provide the first direct evidence that GlcNAcstatins are cell-penetrant compounds.</p>
      </sec>
      <sec id="sec2.5">
        <title>GlcNAcstatins Effectively Induce Cellular Hyper-<italic>O</italic>-GlcNAcylation at Low Nanomolar Concentrations</title>
        <p>The novel GlcNAcstatin derivatives were investigated for their activity on endogenous hOGA in a cell-based assay with HEK293 cells. Cells were exposed for 6 hr to a range of inhibitor concentrations and investigated for an increase of cellular <italic>O</italic>-GlcNAcylation levels by western blotting using an anti-<italic>O</italic>-GlcNAc antibody (CTD110.6), followed by the fitting of densitometric data to a standard dose-response curve (<xref rid="fig3" ref-type="fig">Figure 3</xref>A), yielding EC<sub>50</sub>s of 20 nM for both GlcNAcstatins C and G, and an EC<sub>50</sub> of 290 nM for GlcNAcstatin F. Treatment with concentrations as low as 100 nM of GlcNAcstatin G in the culture media appears to already induce maximum levels of <italic>O</italic>-GlcNAcylation (<xref rid="fig3" ref-type="fig">Figure 3</xref>A). Furthermore, we determined the EC<sub>50</sub> of GlcNAcstatins G and H by <italic>O</italic>-GlcNAc microscopy assay (<xref rid="fig3" ref-type="fig">Figure 3</xref>B; see <xref rid="app3" ref-type="sec">Figure S1</xref> available online). Elevated total <italic>O</italic>-GlcNAc levels in HEK293 cells were quantified and normalized over a reference DAPI signal. Dose-response curves of these analyses yielded EC<sub>50</sub> values of 3 and 42 nM for GlcNAcstatins G and H, respectively, in good agreement with the immunoblotting-derived data (<xref rid="fig3" ref-type="fig">Figures 3</xref>A and 3B).</p>
        <p>In conclusion these new compounds and, in particular, GlcNAcstatin G provide potent and selective chemical biological dissection tools as an attractive alternative to genetic approaches for modulating intracellular <italic>O</italic>-GlcNAc levels in cells to study the role of <italic>O</italic>-GlcNAc in signal transduction.</p>
      </sec>
    </sec>
    <sec id="sec3">
      <title>Significance</title>
      <p>
        <bold>Selective inhibition of human <italic>O</italic>-GlcNAcase is a useful strategy to study the role of the <italic>O</italic>-GlcNAc modification in living cells. Previously reported compounds showed undesirable inhibition of the human lysosomal hexosaminidases, and there has been no direct evidence of the cell penetration of these compounds. This work reports derivatives of the GlcNAcstatin scaffold, showing potent inhibition of human <italic>O</italic>-GlcNAcase with up to 900,000-fold weaker inhibition of the lysosomal hexosaminidases. These are the most selective human <italic>O</italic>-GlcNAcase inhibitors known to date and penetrate live cells to induce cellular hyper-<italic>O</italic>-GlcNAcylation levels with EC<sub>50</sub>s in the low nanomolar range.</bold>
      </p>
    </sec>
    <sec sec-type="methods" id="sec4">
      <title>Experimental Procedures</title>
      <sec id="sec4.1">
        <title>Determination of the <italic>Cp</italic>OGA-GlcNAcstatin F Complex Crystal Structure</title>
        <p>Cloning, expression, purification, and crystallization of hOGA and/or <italic>Cp</italic>OGA have been described previously (<xref rid="bib6" ref-type="bibr">Dorfmueller et al., 2009</xref>). Diffraction data for a <italic>Cp</italic>OGA-V331C GlcNAcstatin F complex were collected on BM-14 (ESRF, Grenoble) to 2.4 Å (<xref rid="tbl2" ref-type="table">Table 2</xref>). Refinement to 2.5 Å resolution was initiated from the protein model in the <italic>Cp</italic>OGA-GlcNAcstatin C complex (PDB entry 2J62) (<xref rid="bib5" ref-type="bibr">Dorfmueller et al. [2006]</xref>), and completed by iterative model building using COOT (<xref rid="bib7" ref-type="bibr">Emsley and Cowtan, 2004</xref>) and refinement with REFMAC (<xref rid="bib18" ref-type="bibr">Murshudov et al., 1997</xref>) (Final R, R<sub>free</sub> at 2.5 Å resolution: 0.197, 0.236).</p>
      </sec>
      <sec id="sec4.2">
        <title>Inhibitor Potency and Mode of Action</title>
        <p>Steady-state kinetics (measurements were performed in triplicate) and inhibition constants (K<sub>i</sub>) for GlcNAcstatin derivatives were determined using the fluorogenic assay as described previously (<xref rid="bib6" ref-type="bibr">Dorfmueller et al., 2009</xref>).</p>
        <p>The mode of inhibition was visually verified by a Lineweaver-Burk plot (<xref rid="fig1" ref-type="fig">Figure 1</xref>B) and the K<sub>i</sub> determined by fitting all fluorescence intensity data to the standard equation for competitive inhibition in GraFit (<xref rid="bib12" ref-type="bibr">Leatherbarrow, 2001</xref>) (<xref rid="tbl1" ref-type="table">Table 1</xref>). IC<sub>50</sub> measurements with hHexA/B (Sigma A6152) activities against GlcNAcstatins F, G, and H were performed using the fluorogenic 4MU-NAG substrate and standard reaction mixtures as described previously (<xref rid="bib6" ref-type="bibr">Dorfmueller et al., 2009</xref>) (<xref rid="fig1" ref-type="fig">Figure 1</xref>C).</p>
      </sec>
      <sec id="sec4.3">
        <title>Cell-Based Assays and Western Blots</title>
        <p>For the <italic>O</italic>-GlcNAc western blots, HEK293 cells were cultured and treated with GlcNAcstatin derivatives as described previously (<xref rid="bib6" ref-type="bibr">Dorfmueller et al., 2009</xref>). Cell lysates were separated by SDS PAGE, and <italic>O</italic>-GlcNAcylation was detected by western blotting with the anti-<italic>O</italic>-GlcNAc CTD110.6 antibody and quantified (<xref rid="bib6" ref-type="bibr">Dorfmueller et al., 2009</xref>). To calculate the EC<sub>50</sub> values of GlcNAcstatins C, F, and G, the data, background corrected with the untreated cells, were plotted against the inhibitor concentrations using the program GraphPad Prism (<ext-link ext-link-type="uri" xlink:href="http://www.graphpad.com">http://www.graphpad.com</ext-link>).</p>
        <p>For the microscopy studies, HEK293 cells were seeded in clear flat-bottom 96 well assay plates (Corning 3340) and grown for 12 hr at 37°C under 5% CO<sub>2</sub>. Cells were treated with concentrations of GlcNAcstatins G and H (1% final DMSO concentration) for 6 hr. Cells were washed twice with 50 μl PBS and fixed in 3.7% formaldehyde for 10 min at 37°C. After washing with TBST (0.1% Triton X-100) and permeabilized for further 10 min, the cells were blocked with 2% BSA and 0.1% normal donkey serum in TBST for 1 hr at RT, followed by washing twice with TBST. Cells were immunostained with the RL2 <italic>O</italic>-GlcNAc antibody (1/500) for 12 hr at 4°C and fluorescent secondary (1/500) for 1 hr at RT. Cells were further washed twice with TBS before incubation with DAPI (5 μg/ml) and CellMask (1/25000). Cells were washed twice with TBS and stored in 50 μl PBS. Images were taken and analyzed with the IN Cell Analyzer 1000 system (GE Healthcare).</p>
      </sec>
      <sec id="sec4.4">
        <title>Determination of Intracellular GlcNAcstatin G Concentration</title>
        <p>HEK293 cells were treated as described above with two concentrations (1 and 10 μM) of GlcNAcstatin G for 1.5 and 6 hr. Cells were washed twice in ice-cold PBS and harvested in lysis buffer. The soluble fraction was separated from cell debris by centrifugation and direct analysis performed by UPLC-MS/MS on a Quattro Premier XE mass spectrometer using positive electrospray ionization (Waters, UK) in multiple reaction-monitoring mode. A calibration curve was constructed in lysis buffer to cover approximately 3 orders of magnitude for GlcNAcstatin G (i.e., 0.25–500 nM). To calculate the minimal intracellular concentration of GlcNAcstatin G, the number and average size (diameter in μm) of cultured HEK293 cells that were used in this study were analyzed using a Cellometer Auto T4 from Nexcelom Bioscience. Subsequently, the maximal intracellular volume was approximated as V = (4/3) × π × r<sup>3</sup>, assuming a spherical cell and ignoring effects of intracellular compartments and proteins. To calculate the total maximal volume of the intracellular volume in a 2 ml culture, the total number of HEK293 cells was calculated and multiplied by the average single-cell volume. This volume was used to determine the minimal dilution factor of the intracellular volume upon cell lysis. To determine the cellular uptake and, thus, the minimal concentration of freely available GlcNAcstatin G, the concentration of the compound determined by UPLC-MS/MS was corrected using the dilution factor.</p>
      </sec>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="bib1">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Akimoto</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Hart</surname>
              <given-names>G.W.</given-names>
            </name>
            <name>
              <surname>Wells</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Vosseller</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Munetomo</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Ohara-Imaizumi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Nishiwaki</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Nagamatsu</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Hirano</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Kawakami</surname>
              <given-names>H.</given-names>
            </name>
          </person-group>
          <article-title>Elevation of the post-translational modification of proteins by O-linked N-acetylglucosamine leads to deterioration of the glucose-stimulated insulin secretion in the pancreas of diabetic Goto-Kakizaki rats</article-title>
          <source>Glycobiology</source>
          <volume>17</volume>
          <year>2007</year>
          <fpage>127</fpage>
          <lpage>140</lpage>
          <pub-id pub-id-type="pmid">17095531</pub-id>
        </element-citation>
      </ref>
      <ref id="bib2">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bowe</surname>
              <given-names>D.B.</given-names>
            </name>
            <name>
              <surname>Sadlonova</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Toleman</surname>
              <given-names>C.A.</given-names>
            </name>
            <name>
              <surname>Novak</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Hu</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Mukherjee</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Whitsett</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Frost</surname>
              <given-names>A.R.</given-names>
            </name>
            <name>
              <surname>Paterson</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Kudlow</surname>
              <given-names>J.E.</given-names>
            </name>
          </person-group>
          <article-title>O-GlcNAc integrates the proteasome and transcriptome to regulate nuclear hormone receptors</article-title>
          <source>Mol. Cell. Biol.</source>
          <volume>26</volume>
          <year>2006</year>
          <fpage>8539</fpage>
          <lpage>8550</lpage>
          <pub-id pub-id-type="pmid">16966374</pub-id>
        </element-citation>
      </ref>
      <ref id="bib3">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chou</surname>
              <given-names>C.F.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>A.J.</given-names>
            </name>
            <name>
              <surname>Omary</surname>
              <given-names>M.B.</given-names>
            </name>
          </person-group>
          <article-title>Characterization and dynamics of O-linked glycosylation of human cytokeratin 8 and 18</article-title>
          <source>J. Biol. Chem.</source>
          <volume>267</volume>
          <year>1992</year>
          <fpage>3901</fpage>
          <lpage>3906</lpage>
          <pub-id pub-id-type="pmid">1371281</pub-id>
        </element-citation>
      </ref>
      <ref id="bib4">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dong</surname>
              <given-names>D.L.,</given-names>
            </name>
            <name>
              <surname>Hart</surname>
              <given-names>G.W.</given-names>
            </name>
          </person-group>
          <article-title>Purification and characterization of an O-GlcNAc selective N-acetyl-beta-D-glucosaminidase from rat spleen cytosol</article-title>
          <source>J. Biol. Chem.</source>
          <volume>269</volume>
          <year>1994</year>
          <fpage>19321</fpage>
          <lpage>19330</lpage>
          <pub-id pub-id-type="pmid">8034696</pub-id>
        </element-citation>
      </ref>
      <ref id="bib5">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dorfmueller</surname>
              <given-names>H.C.</given-names>
            </name>
            <name>
              <surname>Borodkin</surname>
              <given-names>V.S.</given-names>
            </name>
            <name>
              <surname>Schimpl</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Shepherd</surname>
              <given-names>S.M.</given-names>
            </name>
            <name>
              <surname>Shpiro</surname>
              <given-names>N.A.</given-names>
            </name>
            <name>
              <surname>van Aalten</surname>
              <given-names>D.M.F.</given-names>
            </name>
          </person-group>
          <article-title>GlcNAcstatin: a picomolar, selective O-GlcNAcase inhibitor that modulates intracellular O-GlcNAcylation levels</article-title>
          <source>J. Am. Chem. Soc.</source>
          <volume>128</volume>
          <year>2006</year>
          <fpage>16484</fpage>
          <lpage>16485</lpage>
          <pub-id pub-id-type="pmid">17177381</pub-id>
        </element-citation>
      </ref>
      <ref id="bib6">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dorfmueller</surname>
              <given-names>H.C.</given-names>
            </name>
            <name>
              <surname>Borodkin</surname>
              <given-names>V.S.</given-names>
            </name>
            <name>
              <surname>Schimpl</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>van Aalten</surname>
              <given-names>D.M.F.</given-names>
            </name>
          </person-group>
          <article-title>GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation</article-title>
          <source>Biochem. J.</source>
          <volume>420</volume>
          <year>2009</year>
          <fpage>221</fpage>
          <lpage>227</lpage>
          <pub-id pub-id-type="pmid">19275764</pub-id>
        </element-citation>
      </ref>
      <ref id="bib7">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Emsley</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Cowtan</surname>
              <given-names>K.</given-names>
            </name>
          </person-group>
          <article-title>Coot: model-building tools for molecular graphics</article-title>
          <source>Acta Crystallogr. D Biol. Crystallogr.</source>
          <volume>60</volume>
          <year>2004</year>
          <fpage>2126</fpage>
          <lpage>2132</lpage>
          <pub-id pub-id-type="pmid">15572765</pub-id>
        </element-citation>
      </ref>
      <ref id="bib8">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gao</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Wells</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Comer</surname>
              <given-names>F.I.</given-names>
            </name>
            <name>
              <surname>Parker</surname>
              <given-names>G.J.</given-names>
            </name>
            <name>
              <surname>Hart</surname>
              <given-names>G.W.</given-names>
            </name>
          </person-group>
          <article-title>Dynamic O-glycosylation of nuclear and cytosolic proteins: cloning and characterization of a neutral, cytosolic beta-N-acetylglucosaminidase from human brain</article-title>
          <source>J. Biol. Chem.</source>
          <volume>276</volume>
          <year>2001</year>
          <fpage>9838</fpage>
          <lpage>9845</lpage>
          <pub-id pub-id-type="pmid">11148210</pub-id>
        </element-citation>
      </ref>
      <ref id="bib9">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hanover</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Krause</surname>
              <given-names>M.W.</given-names>
            </name>
            <name>
              <surname>Love</surname>
              <given-names>D.C.</given-names>
            </name>
          </person-group>
          <article-title>The hexosamine signaling pathway: O-GlcNAc cycling in feast or famine</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1800</volume>
          <year>2010</year>
          <fpage>80</fpage>
          <lpage>95</lpage>
          <pub-id pub-id-type="pmid">19647043</pub-id>
        </element-citation>
      </ref>
      <ref id="bib10">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hart</surname>
              <given-names>G.W.</given-names>
            </name>
            <name>
              <surname>Housley</surname>
              <given-names>M.P.</given-names>
            </name>
            <name>
              <surname>Slawson</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins</article-title>
          <source>Nature</source>
          <volume>446</volume>
          <year>2007</year>
          <fpage>1017</fpage>
          <lpage>1022</lpage>
          <pub-id pub-id-type="pmid">17460662</pub-id>
        </element-citation>
      </ref>
      <ref id="bib11">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kreppel</surname>
              <given-names>L.K.</given-names>
            </name>
            <name>
              <surname>Blomberg</surname>
              <given-names>M.A.</given-names>
            </name>
            <name>
              <surname>Hart</surname>
              <given-names>G.W.</given-names>
            </name>
          </person-group>
          <article-title>Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats</article-title>
          <source>J. Biol. Chem.</source>
          <volume>272</volume>
          <year>1997</year>
          <fpage>9308</fpage>
          <lpage>9315</lpage>
          <pub-id pub-id-type="pmid">9083067</pub-id>
        </element-citation>
      </ref>
      <ref id="bib12">
        <mixed-citation publication-type="other">Leatherbarrow, R.J. (2001). Version 5, Erithacus Software Ltd., Horley, UK.</mixed-citation>
      </ref>
      <ref id="bib13">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lemieux</surname>
              <given-names>M.J.</given-names>
            </name>
            <name>
              <surname>Mark</surname>
              <given-names>B.L.</given-names>
            </name>
            <name>
              <surname>Cherney</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Withers</surname>
              <given-names>S.G.</given-names>
            </name>
            <name>
              <surname>Mahuran</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>James</surname>
              <given-names>M.N.G.</given-names>
            </name>
          </person-group>
          <article-title>Crystallographic structure of human beta-hexosaminidase A: interpretation of Tay-Sachs mutations and loss of GM2 ganglioside hydrolysis</article-title>
          <source>J. Mol. Biol.</source>
          <volume>359</volume>
          <year>2006</year>
          <fpage>913</fpage>
          <lpage>929</lpage>
          <pub-id pub-id-type="pmid">16698036</pub-id>
        </element-citation>
      </ref>
      <ref id="bib14">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lubas</surname>
              <given-names>W.A.</given-names>
            </name>
            <name>
              <surname>Frank</surname>
              <given-names>D.W.</given-names>
            </name>
            <name>
              <surname>Krause</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hanover</surname>
              <given-names>J.A.</given-names>
            </name>
          </person-group>
          <article-title>O-Linked GlcNAc transferase is a conserved nucleocytoplasmic protein containing tetratricopeptide repeats</article-title>
          <source>J. Biol. Chem.</source>
          <volume>272</volume>
          <year>1997</year>
          <fpage>9316</fpage>
          <lpage>9324</lpage>
          <pub-id pub-id-type="pmid">9083068</pub-id>
        </element-citation>
      </ref>
      <ref id="bib15">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Macauley</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Whitworth</surname>
              <given-names>G.E.</given-names>
            </name>
            <name>
              <surname>Debowski</surname>
              <given-names>A.W.</given-names>
            </name>
            <name>
              <surname>Chin</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Vocadlo</surname>
              <given-names>D.J.</given-names>
            </name>
          </person-group>
          <article-title>O-GlcNAcase uses substrate-assisted catalysis: kinetic analysis and development of highly selective mechanism-inspired inhibitors</article-title>
          <source>J. Biol. Chem.</source>
          <volume>280</volume>
          <year>2005</year>
          <fpage>25313</fpage>
          <lpage>25322</lpage>
          <pub-id pub-id-type="pmid">15795231</pub-id>
        </element-citation>
      </ref>
      <ref id="bib16">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Macauley</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Bubb</surname>
              <given-names>A.K.</given-names>
            </name>
            <name>
              <surname>Martinez-Fleites</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>G.J.</given-names>
            </name>
            <name>
              <surname>Vocadlo</surname>
              <given-names>D.J.</given-names>
            </name>
          </person-group>
          <article-title>Elevation of global O-GlcNAc levels in 3T3-L1 adipocytes by selective inhibition of O-GlcNAcase does not induce insulin resistance</article-title>
          <source>J. Biol. Chem.</source>
          <volume>283</volume>
          <year>2008</year>
          <fpage>34687</fpage>
          <lpage>34695</lpage>
          <pub-id pub-id-type="pmid">18842583</pub-id>
        </element-citation>
      </ref>
      <ref id="bib17">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mark</surname>
              <given-names>B.L.</given-names>
            </name>
            <name>
              <surname>Mahuran</surname>
              <given-names>D.J.</given-names>
            </name>
            <name>
              <surname>Cherney</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Knapp</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>James</surname>
              <given-names>M.N.</given-names>
            </name>
          </person-group>
          <article-title>Crystal structure of human beta-hexosaminidase B: understanding the molecular basis of Sandhoff and Tay-Sachs disease</article-title>
          <source>J. Mol. Biol.</source>
          <volume>327</volume>
          <year>2003</year>
          <fpage>1093</fpage>
          <lpage>1109</lpage>
          <pub-id pub-id-type="pmid">12662933</pub-id>
        </element-citation>
      </ref>
      <ref id="bib18">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Murshudov</surname>
              <given-names>G.N.</given-names>
            </name>
            <name>
              <surname>Vagin</surname>
              <given-names>A.A.</given-names>
            </name>
            <name>
              <surname>Dodson</surname>
              <given-names>E.J.</given-names>
            </name>
          </person-group>
          <article-title>Refinement of macromolecular structures by the maximum-likelihood method</article-title>
          <source>Acta Crystallogr. D Biol. Crystallogr.</source>
          <volume>53</volume>
          <year>1997</year>
          <fpage>240</fpage>
          <lpage>255</lpage>
          <pub-id pub-id-type="pmid">15299926</pub-id>
        </element-citation>
      </ref>
      <ref id="bib19">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nagy</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Balasa</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Frank</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Rab</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Rideg</surname>
              <given-names>O.</given-names>
            </name>
            <name>
              <surname>Kotek</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Magyarlaki</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Bogner</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Kovács</surname>
              <given-names>G.L.</given-names>
            </name>
            <name>
              <surname>Miseta</surname>
              <given-names>A.</given-names>
            </name>
          </person-group>
          <article-title>O-GlcNAc modification of proteins affects volume regulation in Jurkat cells</article-title>
          <source>Eur. Biophys. J.</source>
          <volume>39</volume>
          <year>2009</year>
          <fpage>1207</fpage>
          <lpage>1217</lpage>
          <pub-id pub-id-type="pmid">20043149</pub-id>
        </element-citation>
      </ref>
      <ref id="bib20">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ngoh</surname>
              <given-names>G.A.</given-names>
            </name>
            <name>
              <surname>Facundo</surname>
              <given-names>H.T.</given-names>
            </name>
            <name>
              <surname>Hamid</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Dillmann</surname>
              <given-names>W.</given-names>
            </name>
            <name>
              <surname>Zachara</surname>
              <given-names>N.E.</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>S.P.</given-names>
            </name>
          </person-group>
          <article-title>Unique hexosaminidase reduces metabolic survival signal and sensitizes cardiac myocytes to hypoxia/reoxygenation injury</article-title>
          <source>Circ. Res.</source>
          <volume>104</volume>
          <year>2009</year>
          <fpage>41</fpage>
          <lpage>49</lpage>
          <pub-id pub-id-type="pmid">19023128</pub-id>
        </element-citation>
      </ref>
      <ref id="bib21">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roquemore</surname>
              <given-names>E.P.</given-names>
            </name>
            <name>
              <surname>Chevrier</surname>
              <given-names>M.R.</given-names>
            </name>
            <name>
              <surname>Cotter</surname>
              <given-names>R.J.</given-names>
            </name>
            <name>
              <surname>Hart</surname>
              <given-names>G.W.</given-names>
            </name>
          </person-group>
          <article-title>Dynamic O-GlcNAcylation of the small heat shock protein alpha B-crystallin</article-title>
          <source>Biochemistry</source>
          <volume>35</volume>
          <year>1996</year>
          <fpage>3578</fpage>
          <lpage>3586</lpage>
          <pub-id pub-id-type="pmid">8639509</pub-id>
        </element-citation>
      </ref>
      <ref id="bib22">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stubbs</surname>
              <given-names>K.A.</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Vocadlo</surname>
              <given-names>D.J.</given-names>
            </name>
          </person-group>
          <article-title>A divergent synthesis of 2-acyl derivatives of PUGNAc yields selective inhibitors of O-GlcNAcase</article-title>
          <source>Org. Biomol. Chem.</source>
          <volume>4</volume>
          <year>2006</year>
          <fpage>839</fpage>
          <lpage>845</lpage>
          <pub-id pub-id-type="pmid">16493467</pub-id>
        </element-citation>
      </ref>
      <ref id="bib23">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Torres</surname>
              <given-names>C.R.</given-names>
            </name>
            <name>
              <surname>Hart</surname>
              <given-names>G.W.</given-names>
            </name>
          </person-group>
          <article-title>Topography and polypeptide distribution of terminal N-acetylglucosamine residues on the surfaces of intact lymphocytes. Evidence for O-linked GlcNAc</article-title>
          <source>J. Biol. Chem.</source>
          <volume>259</volume>
          <year>1984</year>
          <fpage>3308</fpage>
          <lpage>3317</lpage>
          <pub-id pub-id-type="pmid">6421821</pub-id>
        </element-citation>
      </ref>
      <ref id="bib24">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vosseller</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Wells</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Lane</surname>
              <given-names>M.D.</given-names>
            </name>
            <name>
              <surname>Hart</surname>
              <given-names>G.W.</given-names>
            </name>
          </person-group>
          <article-title>Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes</article-title>
          <source>Proc. Natl. Acad. Sci. USA</source>
          <volume>99</volume>
          <year>2002</year>
          <fpage>5313</fpage>
          <lpage>5318</lpage>
          <pub-id pub-id-type="pmid">11959983</pub-id>
        </element-citation>
      </ref>
      <ref id="bib25">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yuzwa</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Macauley</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Heinonen</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Shan</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Dennis</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Whitworth</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Stubbs</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>McEachern</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Vocadlo</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo</article-title>
          <source>Nat. Chem. Biol.</source>
          <volume>4</volume>
          <year>2008</year>
          <fpage>483</fpage>
          <lpage>490</lpage>
          <pub-id pub-id-type="pmid">18587388</pub-id>
        </element-citation>
      </ref>
      <ref id="bib26">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zachara</surname>
              <given-names>N.E.</given-names>
            </name>
            <name>
              <surname>Hart</surname>
              <given-names>G.W.</given-names>
            </name>
          </person-group>
          <article-title>Cell signaling, the essential role of O-GlcNAc!</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1761</volume>
          <year>2006</year>
          <fpage>599</fpage>
          <lpage>617</lpage>
          <pub-id pub-id-type="pmid">16781888</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <sec id="app1">
      <title>Accession Numbers</title>
      <p>Coordinates and structure factors are deposited in the RCSB protein data bank (PDB entry 2XPK).</p>
    </sec>
    <sec id="app3" sec-type="supplementary-material">
      <title>Supplemental Information</title>
      <p>
        <supplementary-material content-type="local-data" id="mmc1">
          <caption>
            <title>Document S1. Supplemental Experimental Procedures, Six Figures, and One Table</title>
          </caption>
          <media xlink:href="mmc1.pdf" mimetype="application" mime-subtype="pdf"/>
        </supplementary-material>
      </p>
    </sec>
    <ack>
      <title>Acknowledgments</title>
      <p>We thank the ESRF, Grenoble, for beam time on BM-14. This work was supported by a Wellcome Trust Senior Fellowship and a Lister Institute for Preventive Medicine Research Prize to D.M.F.v. H.C.D. is supported by the College of Life Sciences Alumni Studentship.</p>
    </ack>
  </back>
  <floats-group>
    <fig id="fig1">
      <label>Figure 1</label>
      <caption>
        <p>GlcNAcstatins and Their Inhibitory Activities</p>
        <p>(A) Chemical structures of GlcNAcstatins C, D, and F–H.</p>
        <p>(B) Lineweaver-Burk analysis of hOGA steady-state kinetics measured in the presence of 0–40 nM GlcNAcstatin G at pH 7.3. Data were fitted using the standard equation for competitive inhibition in the GraFit program (<xref rid="bib12" ref-type="bibr">Leatherbarrow, 2001</xref>), yielding a K<sub>i</sub> of 4.1 nM (<xref rid="tbl1" ref-type="table">Table 1</xref>).</p>
        <p>(C) Dose-response curve of hHexA/B inhibition GlcNAcstatins C and F–H. Data were fitted using the standard IC<sub>50</sub> equation in the GraFit program (<xref rid="bib12" ref-type="bibr">Leatherbarrow, 2001</xref>).</p>
        <p>(D) Characterization of pH optimum of hOGA catalytic activity (open circles) and GlcNAcstatin C inhibition (black dots). The catalytic activity was measured using a McIlvaine buffer system over a 4.9–8.1 pH range. Data for 1/K<sub>i</sub> and k<sub>cat</sub>/K<sub>m</sub> were plotted versus the pH and fitted by nonlinear regression to the bell-shaped double pK<sub>a</sub> equation in the program GraphPad Prism. The pH optimum for hOGA hydrolytic activity is pH 7.3 (right <italic>y</italic>-axis), and the pH optimum GlcNAcstatin C inhibition is at pH 6.6 (left <italic>y</italic>-axis).</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
    <fig id="fig2">
      <label>Figure 2</label>
      <caption>
        <p>Binding of GlcNAcstatins to <italic>Cp</italic>OGA</p>
        <p>(A) Comparison of the active-site architecture of OGA enzymes and hexosaminidases. The active site of <italic>Cp</italic>OGA in complex with GlcNAcstatin D (PDB entry 2WB5) (<xref rid="bib6" ref-type="bibr">Dorfmueller et al. [2009]</xref>) is shown in a semitransparent surface representation. GlcNAcstatin D is shown in sticks with green carbon atoms. hHexA in complex with NAG-thiazoline (PDB entry 2GK1) (<xref rid="bib13" ref-type="bibr">Lemieux et al. [2006]</xref>) is shown with NAG-thiazoline in sticks with green carbon atoms. The residues blocking the active site from this side view (Tyr335 in <italic>Cp</italic>OGA and Trp392 in hHexA) have been removed in these images for clarity. Hydrogen bonds between the ligands and active site residues are indicated by black dashed lines.</p>
        <p>(B) Stereo figure of the crystal structure of GlcNAcstatin F (sticks with green carbon atoms) in complex with V331C-<italic>Cp</italic>OGA. Hydrogen bonds are indicated by black dashed lines. An unbiased |F<sub>o</sub> |− |F<sub>c</sub> |, ϕ<sub>calc</sub> electron density map calculated without the model having seen the inhibitor in refinement is shown at 2.75 σ.</p>
        <p>(C) Stereo figure of a superimposition of GlcNAcstatin F onto the hHexA-thiazoline complex. Semitransparent surface representation of hHexA in complex with NAG-thiazoline (green carbon atoms) (PDB entry: 2GK1) (<xref rid="bib13" ref-type="bibr">Lemieux et al. [2006]</xref>). GlcNAcstatin F (magenta carbon atoms) is superimposed onto NAG-thiazoline.</p>
      </caption>
      <graphic xlink:href="gr2"/>
    </fig>
    <fig id="fig3">
      <label>Figure 3</label>
      <caption>
        <p>hOGA Inhibitors GlcNAcstatins G and H Elevate <italic>O</italic>-GlcNAc Levels in HEK293 Cells</p>
        <p>(A) HEK293 cells were incubated with GlcNAcstatins C, F, and G for 6 hr at a range of doses. Cellular <italic>O</italic>-GlcNAcylation levels were qualitatively analyzed using an <italic>O</italic>-GlcNAc antibody. Densitometric quantitation of single western blots (GlcNAcstatins C and F) and of three <italic>O</italic>-GlcNAc western blots (GlcNAcstatin G) reveals EC<sub>50</sub> values of 20 nM for GlcNAcstatin C, 290 nM for GlcNAcstatin F, and 20 nM for GlcNAcstatin G.</p>
        <p>(B) Immunostaining using an <italic>O</italic>-GlcNAc antibody shows an elevation of total <italic>O</italic>-GlcNAc modification (green) of HEK293 cells. Increased concentrations of GlcNAcstatins G and H induce hyper-<italic>O</italic>-GlcNAcylation. Dose-response curves of GlcNAcstatin treatments demonstrate the efficiency of the inhibition. Images were analyzed with the IN cell analyzer, and <italic>O</italic>-GlcNAc signal in each frame was normalized over the DAPI signal (blue). The scale bar represents 20 μm.</p>
        <p>See also <xref rid="app3" ref-type="sec">Figure S1</xref>.</p>
      </caption>
      <graphic xlink:href="gr3"/>
    </fig>
    <table-wrap id="tbl1" position="float">
      <label>Table 1</label>
      <caption>
        <p>Inhibition Data and Selectivity of GlcNAcstatins C and F–H, PUGNAc, and Thiamet-G against Lysosomal hHexA/HexB, Human OGA and <italic>Cp</italic>OGA-WT and V331C-<italic>Cp</italic>OGA Mutant</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th rowspan="2"/>
            <th>K<sub>i</sub> (μM)<hr/></th>
            <th>K<sub>i</sub> (nM)<hr/></th>
            <th>Selectivity<hr/></th>
            <th>K<sub>i</sub> (nM)<hr/></th>
            <th>K<sub>i</sub> (nM)<hr/></th>
          </tr>
          <tr>
            <th>hHex A/B<xref rid="tblfn1" ref-type="table-fn">a</xref></th>
            <th>hOGA<xref rid="tblfn2" ref-type="table-fn">b</xref></th>
            <th>(hHexA/B/hOGA)</th>
            <th><italic>Cp</italic>OGA-wild-type</th>
            <th>V331C-<italic>Cp</italic>OGA</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td>GlcNAcstatin C</td>
            <td align="char">0.6 ± 0.1</td>
            <td align="char">3.2 ± 0.9</td>
            <td>190</td>
            <td align="char">0.0046 ± 0.0002<xref rid="tblfn3" ref-type="table-fn">c</xref></td>
            <td align="char">0.098 ± 0.006<xref rid="tblfn3" ref-type="table-fn">c</xref></td>
          </tr>
          <tr>
            <td>GlcNAcstatin F</td>
            <td align="char">11.0 ± 0.6<xref rid="tblfn4" ref-type="table-fn">d</xref></td>
            <td align="char">11.2 ± 1.4</td>
            <td>1,000</td>
            <td align="char">0.0032 ± 0.0002</td>
            <td align="char">0.005 ± 0.001</td>
          </tr>
          <tr>
            <td>GlcNAcstatin G</td>
            <td>&gt;3,700<xref rid="tblfn4" ref-type="table-fn">d</xref></td>
            <td align="char">4.1 ± 0.7</td>
            <td>&gt;900,000</td>
            <td align="char">0.0078 ± 0.0007</td>
            <td align="char">0.019 ± 0.002</td>
          </tr>
          <tr>
            <td>GlcNAcstatin H</td>
            <td align="char">100 ± 30<xref rid="tblfn4" ref-type="table-fn">d</xref></td>
            <td align="char">2.6 ± 0.3</td>
            <td>35,000</td>
            <td>nd</td>
            <td>nd</td>
          </tr>
          <tr>
            <td>PUGNAc</td>
            <td>0.036<xref rid="tblfn5" ref-type="table-fn">e</xref></td>
            <td>50<sup>e</sup></td>
            <td>ns</td>
            <td>5.4 ± 0.4</td>
            <td>nd</td>
          </tr>
          <tr>
            <td>Thiamet-G</td>
            <td>750<xref rid="tblfn6" ref-type="table-fn">f</xref></td>
            <td>21<xref rid="tblfn6" ref-type="table-fn">f</xref></td>
            <td>35,000</td>
            <td>nd</td>
            <td>nd</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>nd, not determined; ns, no selectivity for hOGA.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tblfn1">
          <label>a</label>
          <p>The Cheng-Prusoff equation (K<sub>i</sub> = IC<sub>50</sub>/(1 + [S]/K<sub>m</sub>)) was used to convert the IC<sub>50</sub> values to an absolute inhibition constant (K<sub>i</sub>).</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tblfn2">
          <label>b</label>
          <p>At physiological pH 7.3.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tblfn3">
          <label>c</label>
          <p>From <xref rid="bib6" ref-type="bibr">Dorfmueller et al. (2009)</xref>.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tblfn4">
          <label>d</label>
          <p>These values are approximate IC<sub>50</sub>s, obtained after including an artificial 100% inhibition point at an inhibitor concentration of 1000 M.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tblfn5">
          <label>e</label>
          <p>From <xref rid="bib15" ref-type="bibr">Macauley et al. (2005)</xref>.</p>
        </fn>
      </table-wrap-foot>
      <table-wrap-foot>
        <fn id="tblfn6">
          <label>f</label>
          <p>From <xref rid="bib25" ref-type="bibr">Yuzwa et al. (2008)</xref>.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="tbl2" position="float">
      <label>Table 2</label>
      <caption>
        <p>Details of Data Collection and Structure Refinement for GlcNAcstatin F Bound to V331C-<italic>Cp</italic>OGA</p>
      </caption>
      <table frame="hsides" rules="groups">
        <thead>
          <tr>
            <th/>
            <th>V331C-<italic>Cp</italic>OGA-GlcNAcstatin F</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td rowspan="3">Unit cell (Å)</td>
            <td>a = 130.2</td>
          </tr>
          <tr>
            <td>b = 145.0</td>
          </tr>
          <tr>
            <td>c = 153.1</td>
          </tr>
          <tr>
            <td>Resolution range (Å)</td>
            <td>20.0–2.4 (2.5–2.4)</td>
          </tr>
          <tr>
            <td>Number of observed reflections</td>
            <td>214,504</td>
          </tr>
          <tr>
            <td>Number of unique reflections</td>
            <td>53,607 (4,916)</td>
          </tr>
          <tr>
            <td>Redundancy</td>
            <td>4.0 (3.6)</td>
          </tr>
          <tr>
            <td>I/σI</td>
            <td>14.7 (2.3)</td>
          </tr>
          <tr>
            <td>Completeness (%)</td>
            <td>95.9 (88.6)</td>
          </tr>
          <tr>
            <td>R<sub>merge</sub></td>
            <td>0.129 (0.606)</td>
          </tr>
          <tr>
            <td>Number of protein residues</td>
            <td>1,170</td>
          </tr>
          <tr>
            <td>Number of water molecules</td>
            <td>454</td>
          </tr>
          <tr>
            <td>R, R<sub>free</sub></td>
            <td>0.197, 0.235</td>
          </tr>
          <tr>
            <td colspan="2">RMSD from ideal geometry</td>
          </tr>
          <tr>
            <td>—Bonds (Å)</td>
            <td>0.01</td>
          </tr>
          <tr>
            <td>—Angles (°)</td>
            <td>1.3</td>
          </tr>
          <tr>
            <td>B-factor RMSD (Å<sup>2</sup>)</td>
            <td/>
          </tr>
          <tr>
            <td>— (backbone bonds)</td>
            <td>31.6</td>
          </tr>
          <tr>
            <td>&lt;B &gt; (Å<sup>2</sup>)</td>
            <td/>
          </tr>
          <tr>
            <td>—Protein</td>
            <td>31.6</td>
          </tr>
          <tr>
            <td>—Inhibitor</td>
            <td>32.1</td>
          </tr>
          <tr>
            <td>—Solvent</td>
            <td>32.9</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn>
          <p>Values in parentheses are for the highest resolution shell. All measured data were included in structure refinement. The space group was I2<sub>1</sub>2<sub>1</sub>2<sub>1</sub>.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>